Targeting enteric bacteria in treatment of inflammatory bowel diseases: Why, how, and when

Current Opinion in Gastroenterology

Volumn 19, Issue 4, 2003, Pages 358-365

  Sartor, R Balfour ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; BACTERIAL DNA; BUDESONIDE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELL ADHESION MOLECULE; CIPROFLOXACIN; CORTICOSTEROID; CYTOKINE; CYTOPLASMIC RECEPTOR; FRUCTOSE OLIGOSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INULIN; LACTULOSE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESALAZINE; METRONIDAZOLE; ORNIDAZOLE; PEPTIDOGLYCAN; PROBIOTIC AGENT; PROTEIN NOD1; RIFAXIMIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VSL 3;

ANTIBIOTIC THERAPY; BACTERIAL GROWTH; BACTERIUM; BACTERIUM ADHERENCE; BARLEY; BIFIDOBACTERIUM; CLEARANCE; CLINICAL TRIAL; COLON CROHN DISEASE; COLON RESECTION; COMMENSALISM; CROHN DISEASE; CYTOKINE PRODUCTION; DIET THERAPY; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; ENTEROCOLITIS; ESCHERICHIA COLI; EXPERIMENTAL MODEL; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HUMAN; ILEITIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; INTESTINE FLORA; LACTOBACILLUS; MOLECULAR RECOGNITION; MUCOSAL IMMUNITY; MYCOBACTERIUM PARATUBERCULOSIS; NONHUMAN; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; RECURRENT DISEASE; RELAPSE; REVIEW; SEROLOGY; SIDE EFFECT; STREPTOCOCCUS SALIVARIUS; ULCERATIVE COLITIS;

EID: 0038337828     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200307000-00006     Document Type: Review

References (77)

1. nd ed. New York: Raven Press, 2002:383-413.
2. th ed. Elsevier Publishers, 2003:in press.
3. Farrell RJ, LaMont JT: Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2003, 31:41-62.
4. nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002:45-56.
5. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
6. Barton GM, Medzhitov R: Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002, 270:81-92.
7. Abreu MT, Arnold ET, Thomas LS, et al.: TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002, 277:20431-20437.
8. Gutierrez O, Pipaon C, Inohara N, et al.: Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kB activation. J Biol Chem 2002, 277:41701-41705.
9. Rosenstiel P, Fantini M, Brautigam K, et al.: TNF-alpha and IFN-gamma regulate the expression of NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003, 124:1001-1009.
10. Hisamatsu T, Suzuki M, Reinecker HC, et al.: CARD15/NOD2 functions as an anti-bacterial factor in human intestinal epithelial cells. Gastroenterology 2003, 124:993-1000. Shows that NOD2 functions to enhance clearance of intracellular bacterial pathogens (Salmonella) and that the Crohn disease truncation mutant of NOD2 has loss of function in clearing this organism.
11. Haller D, Russo MP, Sartor RB, et al.: IKKbeta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem 2002, 277:38168-38178. Commensal gram-negative bacteria (E. coli or B. vulgatus) or LPS activate NFκB through TLR-4 binding in colonic epithelial cells in vitro and in vivo.
12. Bonen DK, Ogura Y, Nicolae DL, et al.: Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003, 124:140-146.
13. Klein W, Tromm A, Griga T, et al.: A polymorphism in the CD14 gene is associated with Crohn disease. Scand J Gastroenterol 2002, 37:189-191.
14. Zouali H, Lesage S, Merlin F, et al.: CARD4/NOD1 is not involved in inflammatory bowel disease. Gut 2003, 52:71-74.
15. Engle SJ, Ormsby I, Pawlowski S, et al.: Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 2002, 62:6362-6366.
16. Balish E, Warner T: Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol 2002, 160:2253-2257.
17. Kim SC, Tonkonogy SL, Albright CA, et al.: Regional and host specificity of colitis in mice monoassociated with different nonpathogenic bacteria [abstract]. Gastroenterology 2003, 124:A485.
18. Sellon RK, Tonkonogy S, Schultz M, et al.: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998, 66:5224-5231.
19. Rath HC, Wilson KH, Sartor RB: Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus and Escherichia coli. Infect Immun 1999, 67:2969-2974.
20. Dieleman LA, Arends A, Tonkonogy SL, et al.: Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. Infect Immun 2000, 68:5107-5113.
21. Sydora BC, Tavernini MM, Jewell LD, et al.: Effect of bacterial monoassociation on tolerance and intestinal inflammation in IL-10 gene-deficient mice [abstract]. Gastroenterology 2001, 120:A517.
22. Mann BA, Kim SC, Sartor RB: Selective induction of experimental colitis by monoassociation of HLA-B27 transgenic rats with various enteric Bacteroides species [abstract]. Gastroenterology 2003, 124:A322.
23. Maggio-Price L, Shows D, Waggie K, et al.: Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol 2002, 160:739-751.
24. + T cells to immunodeficient mice, demonstrating that commensal enteric bacteria can induce regulatory (protective) T cells.
25. Kullberg MC, Jankovic D, Gorelick PL, et al.: Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis. J Exp Med 2003, 196:505-515.
26. Rietdijk ST, Faubion W, Albright C, et al.: CD4+ CD25+ regulatory T cells originating from germ free mice have impaired suppressive abilities [abstract]. Gastroenterology 2002, 122:A387.
27. Swidsinski A, Ladhoff A, Pernthaler A, et al.: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44-54. Mucosally associated anaerobic and aerobic enteric bacteria are dramatically increased in Crohn disease and ulcerative colitis, with an intermediate level seen in self-limited intestinal inflammation.
28. Neut C, Bulois P, Desreumaux P, et al.: Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002, 97:939-946.
29. Darfeuille-Michaud A, Neut C, Barnich N, et al.: Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998, 115:1405-1413.
30. Rayment N, Mylonaki M, Rampton D, et al.: Co-localisation of E. coli with macrophages in lamina propria in patients with active inflammatory bowel disease (IBD) [abstract]. Gut 2003, in press.
31. Ohkusa T, Sato N, Ogihara T, et al.: Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 2002, 17:849-853.
32. Linskens RK, Mallant-Hent RC, Groothuismink ZM, et al.: Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol 2002, 14:1013-1018.
33. Landers CJ, Cohavy O, Misra R, et al.: Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123:689-699. Crohn disease patients have serologic responses to several defined bacterial antigens, with evidence of discrete patterns of serologic responses in groups of patients, possibly defining disease subsets.
34. Duffy M, O'Mahony L, Coffey JC, et al.: Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002, 45:384-388.
35. Weiss ST: Eat dirt: the hygiene hypothesis and allergic diseases. N Engl J Med 2002, 347:930-931.
36. Mishkin D, Boston FM, Blank D, et al.: The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease. Dig Dis Sci 2002, 47:489-494.
37. Ryan P, Bennett MW, Aarons S, et al.: PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection. Gut 2002, 51:665-670.
38. Naser SA, Shafran I, Schwartz D, et al.; In situ identification of mycobacteria in Crohn's disease patient tissue using confocal scanning laser microscopy. Mol Cell Probes 2002, 16:41-48.
39. Lund BM, Gould GW, Rampling AM: Pasteurization of milk and the heat resistance of Mycobacterium avium subsp. paratuberculosis: a critical review of the data. Int J Food Microbiol 2002, 77:135-145.
40. Shafran I, Piromalli C, Decker JW, et al.: Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohn's disease patients. Dig Dis Sci 2002, 47:2079-2081.
41. Borody TJ, Leis S, Warren EF, et al.: Treatment of severe Crohn's disease using antimycobacterial triple therapy: pproaching a cure? Dig Liver Dis 2002, 34:29-38.
42. Shafran I, Kugler L, el-Zaatari FA, et al.: Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis 2002, 34:22-28.
43. Hermon-Taylor J, Bull T: Crohn's disease caused by Mycobacterium avium subspecies paratuberculosis: a public health tragedy whose resolution is long overdue. J Med Microbiol 2002, 51:3-6.
44. Bamias G, Marini M, Moskaluk CA, et al.: Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 2002, 169:5308-5314.
45. Rath HC, Schultz M, Freitag R, et al.: Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001, 69:2277-2285.
46. Arnold GL, Beaves MR, Pryjdun VO, et al.: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002, 8:10-15.
47. Steinhart AH, Feagan BG, Wong CJ, et al.: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002, 123:33-40. Combination of ciprofloxacin, metronidazole, and budesonide offers no benefit over budesonide alone in treatment of ileal Crohn disease but may help treat Crohn colitis, showing the importance of distinguishing ileal from colonic involvement in antibiotic trials of Crohn disease.
48. Rutgeerts P, Van Assche G, D'Haens G, et al.: Ornidazole for prophylaxis of postoperative Crohn's disease: final results of a double blind placebo controlled trial [abstract]. Gastroenterology 2002, 122:A80.
49. Mantzaris GJ, Petraki K, Archavlis E, et al.: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001, 36:971-974.
50. Brigidi P, Swennen E, Rizzello F, et al.: Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002, 14:290-295.
51. Lukas M, Konecny M, Zboril V: Rifaximin in patients with mild to moderate activity of ulcerative colitis: an open label study [abstract]. Gastroenterology 2003, A434.
52. Shen B, Achkar JP, Lashner BA, et al.: A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001, 7:301-305.
53. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
54. Schultz M, Rath HC: The possible role of probiotic therapy in inflammatory bowel disease. In: Tannock GW, ed. Probiotics and Prebiotics: Where are We Going? Wymondham, UK: Caister Academic Press, 2002:175-237.
55. Hart AL, Stagg AJ, Frame M, et al.: The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther 2002, 16:1383-1393.
56. Gionchetti P, Amadini C, Rizzello F, et al.: Probiotics: role in inflammatory bowel disease. Dig Liver Dis 2002, 34:S58-S62.
57. Hart AL, Kamm MA: Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003, 36:111-119.
58. Mimura T, Rizzello F, Schreiber S, et al.: Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomised, placebo-controlled, double-blind trial [abstract]. Gastroenterology 2002, 122:A81.
59. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 2003, 124:1202-1209. Evidence that prophylactic use of a probiotic cocktail decreases onset of pouchitis and decreases stool frequency after creation of an ileal pouch/anal anastomosis following colectomy for ulcerative colitis.
60. Kuisma J, Mentula S, Jarvinen H, et al.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
61. Prantera C, Scribano ML, Falasco G, et al.: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002, 51:405-409.
62. Fedorak RN, Gionchetti P, Campieri M, et al.: VSL3 probiotic mixture induces remission in patients with active ulcerative colitis [abstract]. Gastroenterology 2003, 124:A377.
63. Dieleman LA, Goerres M, Arends A, et al.: Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 2003, 52:370-376. Sequential use of broad-spectrum antibiotics and selective probiotic species can prevent recurrence of experimental colitis.
64. Madsen K, Jijon H, Yeung H, et al.: DNA from probiotic bacteria exerts anti-inflammatory actions on intestinal epithelial cells by inhibition of NF-kappa B [abstract]. Gastroenterology 2002, 122:A64.
65. Rachmilewitz D, Karmeli F, Takabayashi K, et al.: Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002, 122:1428-1441. Novel evidence that certain bacterial DNA motifs can prevent colitis, even though this DNA has adjuvant effects on innate immune responses in vitro.
66. Rachmilewitz D, Karmeli F, Lee J, et al.: Immunostimulatory DNA sequences decrease the enhanced colonic TNFa and IL-1b generation in IBD [abstract]. Gastroenterology 2002, 122:A148.
67. Ulisse S, Gionchetti P, D'Alo S, et al.: Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001, 96:2691-2699.
68. Cender CJ, Haller D, Walters C, et al.: VSL #3 alters cytokine production of unfractionated splenocytes upon stimulation with cecal bacterial lysate: immunomodulation by this probiotic combination [abstract]. Gastroenterology 2002, 122:A145.
69. Borruel N, Carol M, Casellas F, et al.: Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002, 51:659-664.
70. Bocker U, Nebe T, Herweck F, et al.: Butyrate modulates intestinal epithelial cell-mediated neutrophil migration. Clin Exp Immunol 2003, 131:53-60.
71. Kleessen B, Hartmann L, Blaut M: Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr 2001, 86:291-300.
72. Fukuda M, Kanauchi O, Araki Y, et al.: Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med 2002, 9:65-70.
73. Videla S, Vilaseca J, Antolin M, et al.: Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 2001, 96:1486-1493.
74. Jeffers M, McDonald WF, Chillakuru RA, et al.: A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 2002, 123:1151-1162.
75. Nakase H, Peterson J, Benedele A, et al.: FGF-20 prevents and treats T-cell mediated colitis by promoting epithelial restitution and stimulating immunosuppressive pathways [abstract]. Gastroenterology 2003, 124:A491.
76. Suenaert P, Bulteel V, Lemmens L, et al.: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002, 97:2000-2004.
77. Schultz M, Veltkamp C, Dieleman LA, et al.: Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10 deficient mice. Inflamm Bowel Dis 2002, 8:71-80.